AZD-5069 is primarily investigated for its potential therapeutic applications in the field of respiratory diseases. It is a selective antagonist of the CXCR2 receptor, which plays a significant role in neutrophil migration and inflammation. By blocking this receptor, AZD-5069 aims to reduce inflammation in conditions such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Clinical studies have explored its efficacy in decreasing exacerbations and improving lung function in patients with these chronic respiratory conditions. Additionally, its anti-inflammatory properties are being studied for potential use in other inflammatory diseases where neutrophil activity is a key factor. Research continues to evaluate its safety, tolerability, and long-term benefits in various clinical settings.